Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK3 | P27361 | 2/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | PDE5A | O76074 | 2/20 | 0.32 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAT2A | P31153 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 2/20 | 0.31 |
| ▸ | GSK3A | P49840 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15401021 | 1.00 | MAPK3 (0.38) | MAPK3HCRTR1HCRTR2PDE5AOGFRL1 | |
| SCHEMBL9970907 | 0.88 | TP53 (0.37) | MAPT | |
| SCHEMBL9970823 | 0.85 | BTK (0.34) | BTK | |
| SCHEMBL15400717 | 0.84 | HTR3A (0.34) | BTK | |
| SCHEMBL9970824 | 0.84 | CDK7 (0.36) | JAK2 | |
| SCHEMBL16188366 | 0.82 | PDE5A (0.35) | PDE5AGSK3AGSK3B | |
| SCHEMBL9941696 | 0.80 | GSK3A (0.41) | JAK2GSK3AGSK3B | |
| SCHEMBL9970822 | 0.80 | GSK3A (0.41) | JAK2GSK3AGSK3B | |
| SCHEMBL15401009 | 0.80 | GSK3A (0.41) | JAK2GSK3AGSK3B | |
| SCHEMBL9970868 | 0.78 | GSK3A (0.34) | JAK2GSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140005197-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-02 | — | — | US | disclosed |
| EP-2651941-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | Vertex Pharmaceuticals Incorporated (US) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012083121-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005197-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | ACE, RNASEH1, ACE2 | MAPK3 1155/4885HCRTR1 3496/4885HCRTR2 4174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.